The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Academic Article uri icon


  • Because two-thirds of patients with Major Depressive Disorder do not achieve remission with their first antidepressant, we designed a trial of three "next-step" strategies: switching to another antidepressant (bupropion-SR) or augmenting the current antidepressant with either another antidepressant (bupropion-SR) or with an atypical antipsychotic (aripiprazole). The study will compare 12-week remission rates and, among those who have at least a partial response, relapse rates for up to 6 months of additional treatment. We review seven key efficacy/effectiveness design decisions in this mixed "efficacy-effectiveness" trial.

published proceedings

  • Psychiatry Res

altmetric score

  • 8

author list (cited authors)

  • Mohamed, S., Johnson, G. R., Vertrees, J. E., Guarino, P. D., Weingart, K., Young, I. T., ... Zisook, S.

citation count

  • 16

complete list of authors

  • Mohamed, Somaia||Johnson, Gary R||Vertrees, Julia E||Guarino, Peter D||Weingart, Kimberly||Young, Ilanit Tal||Yoon, Jean||Gleason, Theresa C||Kirkwood, Katherine A||Kilbourne, Amy M||Gerrity, Martha||Marder, Stephen||Biswas, Kousick||Hicks, Paul||Davis, Lori L||Chen, Peijun||Kelada, AlexandraMary||Huang, Grant D||Lawrence, David D||LeGwin, Mary||Zisook, Sidney

publication date

  • October 2015